Izrael -
hebrejština -
Ministry of Health
ארלידה
j-c health care ltd - apalutamide - טבליות מצופות פילם - apalutamide 60 mg - apalutamide
Izrael -
hebrejština -
Ministry of Health
דוטאסטריד טבע
teva israel ltd - dutasteride - קפסולות רכות - dutasteride 0.5 mg - dutasteride
Izrael -
hebrejština -
Ministry of Health
טאדם 10
unipharm ltd, israel - tadalafil - טבליות מצופות פילם - tadalafil 10 mg - tadalafil
Izrael -
hebrejština -
Ministry of Health
טאדם 20
unipharm ltd, israel - tadalafil - טבליות מצופות פילם - tadalafil 20 mg - tadalafil
Izrael -
hebrejština -
Ministry of Health
טאדם 5
unipharm ltd, israel - tadalafil - טבליות מצופות פילם - tadalafil 5 mg - tadalafil
Izrael -
hebrejština -
Ministry of Health
דוטאסטמד
inovamed pharma ltd, israel - dutasteride; tamsulosin hydrochloride - קפסולה קשיחה - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin
Izrael -
hebrejština -
Ministry of Health
ערמוניה פלוס
unipharm trading ltd, israel - dutasteride; tamsulosin hydrochloride - קפסולה קשיחה - tamsulosin hydrochloride 0.4 mg; dutasteride 0.5 mg - tamsulosin and dutasteride
Izrael -
hebrejština -
Ministry of Health
טברקטה 150 מג
novartis israel ltd - capmatinib as dihydrochloride monohydrate - טבליות מצופות פילם - capmatinib as dihydrochloride monohydrate 150 mg - capmatinib
Izrael -
hebrejština -
Ministry of Health
טברקטה 200 מג
novartis israel ltd - capmatinib as dihydrochloride monohydrate - טבליות מצופות פילם - capmatinib as dihydrochloride monohydrate 200 mg - capmatinib
Izrael -
hebrejština -
Ministry of Health
אוקסאאר 50 מג
organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar